Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

SCRI Development Innovations, LLC

Home Clinical Trial Sponsors and OrganizationsSCRI Development Innovations, LLC

SCRI Development Innovations, LLC

ACTIVE

Private

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

179

0 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 2

130

72.6%

Phase 1

33

18.4%

Phase 3

4

2.2%

Not Applicable

2

1.1%

Trial Status Distribution

Completed

148

82.7%

Recruiting

6

3.4%

Terminated

18

10.1%

Withdrawn

7

3.9%

Clinical Trials

Trials sponsored by this organization (179)

A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

Sep 202646 participants

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)

Sep 202560 participants

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

Aug 2025100 participants

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

Mar 2025250 participants

Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Oct 2023100 participants

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Jul 202336 participants

A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer

May 2021121 participants

Page 1 of 23

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials179
Approvals
News

Back to Organizations